WHO approves first mpox diagnostic test for emergency use
Adds background throughout
Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
The real-time PCR test, Alinity m MPXV assay, enables detection of mpox virus DNA from human skin lesion swabs, the WHO said, adding that it was designed for use by trained clinical laboratory personnel.
The agency said it was evaluating three new mpox diagnostic tests for emergency use and was also in discussions with other manufacturers to expand the availability of mpox diagnostic tools.
"This first mpox diagnostic test listed under the Emergency Use Listing (EUL) procedure represents a significant milestone in expanding testing availability in affected countries," said Yukiko Nakatani, agency's assistant director-general for access to medicines and health products.
In August, WHOasked manufacturers to submit their products for an emergency review and has been in discussion with them about the need for effective diagnostics, particularly in low-income groups.
The EUL procedure is a risk-based assessment of unlicensed vaccines, tests and treatments to expedite their availability during public health emergencies.
The WHO declared mpox a global public health emergency for the second time in two years in August, following an outbreak of the viral infection in the Democratic Republic of Congo, which has spread to neighbouring Burundi, Uganda and Rwanda.
Two strains of mpox are spreading - the clade I variant, which is endemic in parts of West and Central Africa and a new, more transmissible strain clade Ib, which has triggered global concern.
Sweden, Thailand, and India have confirmed cases of the clade Ib type of the virus, outside of the Democratic Republic of Congo and neighboring countries.
Reporting by Mariam Sunny and Akash Sriram in Bengaluru; Editing by Mohammed Safi Shamsi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
